The role of neurotensin in positive reinforcement in the rat central nucleus of amygdala

Behavioural Brain Research

Volumn 208, Issue 2, 2010, Pages 430-435

  László, Kristóf ^a   Tóth, Krisztián ^a   Kertes, Erika ^a   Péczely, László ^a   Lénárd, László ^a  

^a UNIVERSITY OF PÉCS   (Hungary)

Author keywords

Central nucleus of amygdala; Conditioned place preference; Neurotensin; NT receptor 1 antagonist; Reinforcement

Indexed keywords

NEUROTENSIN; NEUROTENSIN RECEPTOR;

AMYGDALOID NUCLEUS; ANIMAL TISSUE; ANXIETY; ARTICLE; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; EMOTIONALITY; FEEDING; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LEARNING; LIMBIC SYSTEM; MALE; MAZE TEST; MEMORY; NEUROMODULATION; NEUROTRANSMISSION; NONHUMAN; PLACE PREFERENCE; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT; REINFORCEMENT;

AMYGDALA; ANIMALS; BEHAVIOR, ANIMAL; CONDITIONING, OPERANT; MALE; MAZE LEARNING; MICROINJECTIONS; MOTOR ACTIVITY; NEUROTENSIN; PYRAZOLES; QUINOLINES; RATS; RATS, WISTAR; RECEPTORS, NEUROTENSIN; REINFORCEMENT (PSYCHOLOGY); STATISTICS, NONPARAMETRIC;

EID: 77249155055     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2009.12.022     Document Type: Article

References (68)

1. Adachi D.K., Kalivas P.W., and Schenk J.O. Neurotensin binding to dopamine. J Neurochem 54 (1990) 1321-1328
2. Agnati L.F., Fuxe K., Benfenati F., and Battistini N. Neurotensin in vitro markedly reduces the affinity in subcortical limbic 3H-N-propylnorapomorphine binding sites. Acta Physiol Scand 119 (1983) 459-461
3. Bean A.J., Adrian T.E., Modlin I.M., and Roth R.H. Dopamine and neurotensin storage in colocalized and noncolocalized neuronal populations. J Pharmacol Exp Ther 249 (1989) 681-687
4. Bean A.J., During M.J., Deutch A.Y., and Roth R.H. Effects of dopamine depletion on striatal neurotensin: biochemical and immunohistochemical studies. J Neurosci 9 (1989) 4430-4438
5. Boudin H., Pelaprat D., Rostene W., and Beaudet A. Cellular distribution of neurotensin receptors in rat brain: immunohistochemical study using an antipeptide antibody against the cloned high affinity receptor. J Comp Neurol 373 (1996) 76-89
6. Brouard A., Heaulme M., Leyris R., Pelaprat D., Gully D., Kitabgi P., et al. SR 48692 inhibits neurotensin-induced [3H]dopamine release in rat striatal slices and mesencephalic cultures. Eur J Pharmacol 253 (1994) 289-291
7. Brown E.E., and Fibiger H.C. Differential effects of excitotoxic lesions of the amygdala on cocaine-induced conditioned locomotion and conditioned place preference. Psychopharmacology (Berl) 113 (1993) 123-130
8. Caine S.B., Heinrichs S.C., Coffin V.L., and Koob G.F. Effects of the dopamine D-1 antagonist SCH 23390 microinjected into the accumbens, amygdala or striatum on cocaine self-administration in the rat. Brain Res 692 (1995) 47-56
9. Carraway R., and Leeman S.E. The isolation of a new hypotensive peptide, neurotensin, from bovine hypothalami. J Biol Chem 248 (1973) 6854-6861
10. Conlon J.M., Adrian T.E., and Secor S.M. Tachykinins (substance P, neurokinin A and neuropeptide gamma) and neurotensin from the intestine of the Burmese python, Python molurus. Peptides 18 (1997) 1505-1510
11. Cooper P.E., Fernstrom M.H., Rorstad O.P., Leeman S.E., and Martin J.B. The regional distribution of somatostatin, substance P and neurotensin in human brain. Brain Res 218 (1981) 219-232
12. Davis M., Rainnie D., and Cassell M. Neurotransmission in the rat amygdala related to fear and anxiety. Trends Neurosci 17 (1994) 208-214
13. Dobner P.R. Neurotensin and pain modulation. Peptides 27 (2006) 2405-2414
14. Dubuc I., Costentin J., Terranova J.P., Barnouin M.C., Soubrie P., Le Fur G., et al. The nonpeptide neurotensin antagonist, SR 48692, used as a tool to reveal putative neurotensin receptor subtypes. Br J Pharmacol 112 (1994) 352-354
15. Emson P.C., Goedert M., Benton H., St-Pierre S., and Rioux F. The regional distribution and chromatographic characterization of neurotensin-like immunoreactivity in the rat. Adv Biochem Psychopharmacol 33 (1982) 477-485
16. Ervin G.N., Birkemo L.S., Nemeroff C.B., and Prange Jr. A.J. Neurotensin blocks certain amphetamine-induced behaviours. Nature 291 (1981) 73-76
17. Faggin B.M., Zubieta J.K., Rezvani A.H., and Cubeddu L.X. Neurotensin-induced dopamine release in vivo and in vitro from substantia nigra and nucleus caudate. J Pharmacol Exp Ther 252 (1990) 817-825
18. Fallon J.H., Koziell D.A., and Moore R.Y. Catecholamine innervation of the basal forebrain. II. Amygdala, suprarhinal cortex and entorhinal cortex. J Comp Neurol 180 (1978) 509-532
19. Fantegrossi W.E., Ko M.C., Woods J.H., and Richelson E. Antinociceptive, hypothermic, hypotensive, and reinforcing effects of a novel neurotensin receptor agonist, NT69L, in rhesus monkeys. Pharmacol Biochem Behav 80 (2005) 341-349
20. Fekete E., Vigh J., Bagi E.E., and Lenard L. Gastrin-releasing peptide microinjected into the amygdala inhibits feeding. Brain Res 955 (2002) 55-63
21. Fernandez A., de Ceballos M.L., Jenner P., and Marsden C.D. Neurotensin, substance P, delta and mu opioid receptors are decreased in basal ganglia of Parkinson's disease patients. Neuroscience 61 (1994) 73-79
22. Ferris C.F., Hammer R.A., and Leeman S.E. Elevation of plasma neurotensin during lipid perfusion of rat small intestine. Peptides 2 Suppl. 2 (1981) 263-266
23. Fuxe K., O'Connor W.T., Antonelli T., Osborne P.G., Tanganelli S., Agnati L.F., et al. Evidence for a substrate of neuronal plasticity based on pre- and postsynaptic neurotensin-dopamine receptor interactions in the neostriatum. Proc Natl Acad Sci USA 89 (1992) 5591-5595
24. Glimcher P.W., Giovino A.A., and Hoebel B.G. Neurotensin self-injection in the ventral tegmental area. Brain Res 403 (1987) 147-150
25. Glimcher P.W., Margolin D.H., Giovino A.A., and Hoebel B.G. Neurotensin: a new 'reward peptide'. Brain Res 291 (1984) 119-124
26. Goedert M., Pittaway K., Williams B.J., and Emson P.C. Specific binding of tritiated neurotensin to rat brain membranes: characterization and regional distribution. Brain Res 304 (1984) 71-81
27. Gully D., Canton M., Boigegrain R., Jeanjean F., Molimard J.C., Poncelet M., et al. Biochemical and pharmacological profile of a potent and selective nonpeptide antagonist of the neurotensin receptor. Proc Natl Acad Sci USA 90 (1993) 65-69
28. Harding P.J., Attrill H., Boehringer J., Ross S., Wadhams G.H., Smith E., et al. Constitutive dimerization of the G-protein coupled receptor, neurotensin receptor 1, reconstituted into phospholipid bilayers. Biophys J 96 (2009) 964-973
29. Hetier E., Boireau A., Dubedat P., and Blanchard J.C. Neurotensin effects on evoked release of dopamine in slices from striatum, nucleus accumbens and prefrontal cortex in rat. Naunyn Schmiedebergs Arch Pharmacol 337 (1988) 13-17
30. Hokfelt T., Everitt B.J., Theodorsson-Norheim E., and Goldstein M. Occurrence of neurotensinlike immunoreactivity in subpopulations of hypothalamic, mesencephalic, and medullary catecholamine neurons. J Comp Neurol 222 (1984) 543-559
31. Introini-Collison I.B., Nagahara A.H., and McGaugh J.L. Memory enhancement with intra-amygdala post-training naloxone is blocked by concurrent administration of propranolol. Brain Res 476 (1989) 94-101
32. Kalivas P.W. Neurotransmitter regulation of dopamine neurons in the ventral tegmental area. Brain Res Brain Res Rev 18 (1993) 75-113
33. Kalivas P.W., Nemeroff C.B., and Prange Jr. A.J. Increase in spontaneous motor activity following infusion of neurotensin into the ventral tegmental area. Brain Res 229 (1981) 525-529
34. Kertes E., Laszlo K., Berta B., and Lenard L. Effects of substance P microinjections into the globus pallidus and central nucleus of amygdala on passive avoidance learning in rats. Behav Brain Res 198 (2009) 397-403
35. Kertes E., Laszlo K., Berta B., and Lenard L. Positive reinforcing effects of substance P in the rat central nucleus of amygdala. Behav Brain Res 205 (2009) 307-310
36. Killcross S., Robbins T.W., and Everitt B.J. Different types of fear-conditioned behaviour mediated by separate nuclei within amygdala. Nature 388 (1997) 377-380
37. Kilts C.D., and Anderson C.M. Mesoamygdaloid dopamine neurons: differential rates of dopamine turnover in discrete amygdaloid nuclei of the rat brain. Brain Res 416 (1987) 402-408
38. Kinkead B., and Nemeroff C.B. Neurotensin, schizophrenia, and antipsychotic drug action. Int Rev Neurobiol 59 (2004) 327-349
39. Koob G.F. Drugs of abuse: anatomy, pharmacology and function of reward pathways. Trends Pharmacol Sci 13 (1992) 177-184
40. Le F., Cusack B., and Richelson E. The neurotensin receptor: is there more than one subtype?. Trends Pharmacol Sci 17 (1996) 1-3
41. LeDoux J.E., Iwata J., Cicchetti P., and Reis D.J. Different projections of the central amygdaloid nucleus mediate autonomic and behavioral correlates of conditioned fear. J Neurosci 8 (1988) 2517-2529
42. Lee Y.C., Uttenthal L.O., Smith H.A., and Bloom S.R. In vitro degradation of neurotensin in human plasma. Peptides 7 (1986) 383-387
43. Lu Y.F., Moriwaki A., Hayashi Y., Tomizawa K., Itano T., and Matsui H. Effects of neurotensin on neurons in the rat central amygdaloid nucleus in vitro. Brain Res Bull 40 (1996) 135-141
44. Markstein R., and Emson P. Effect of neurotensin and its fragments neurotensin-(1-6) and neurotensin-(8-13) on dopamine release from cat striatum. Eur J Pharmacol 152 (1988) 147-152
45. McDermott J.R., Smith A.I., Edwardson J.A., and Griffiths E.C. Mechanism of neurotensin degradation by rat brain peptidases. Regul Pept 3 (1982) 397-404
46. McGaugh J.L., Introini-Collison I.B., Cahill L.F., Castellano C., Dalmaz C., Parent M.B., et al. Neuromodulatory systems and memory storage: role of the amygdala. Behav Brain Res 58 (1993) 81-90
47. Moyse E., Rostene W., Vial M., Leonard K., Mazella J., Kitabgi P., et al. Distribution of neurotensin binding sites in rat brain: a light microscopic radioautographic study using monoiodo [125I]Tyr3-neurotensin. Neuroscience 22 (1987) 525-536
48. Myers R.D., and Lee T.F. Neurotensin perfusion of rat hypothalamus: dissociation of dopamine release from body temperature change. Neuroscience 12 (1984) 241-253
49. Nalivaiko E., Michaud J.C., Soubrie P., and Le Fur G. Electrophysiological evidence for putative subtypes of neurotensin receptors in guinea-pig mesencephalic dopaminergic neurons. Neuroscience 86 (1998) 799-811
50. O'Dell L.E., Sussman A.N., Meyer K.L., and Neisewander J.L. Behavioral effects of psychomotor stimulant infusions into amygdaloid nuclei. Neuropsychopharmacology 20 (1999) 591-602
51. Poncelet M., Gueudet C., Gully D., Soubrie P., and Le Fur G. Turning behavior induced by intrastriatal injection of neurotensin in mice: sensitivity to non-peptide neurotensin antagonists. Naunyn Schmiedebergs Arch Pharmacol 349 (1994) 57-60
52. Pugsley T.A., Akunne H.C., Whetzel S.Z., Demattos S., Corbin A.E., Wiley J.N., et al. Differential effects of the nonpeptide neurotensin antagonist, SR 48692, on the pharmacological effects of neurotensin agonists. Peptides 16 (1995) 37-44
53. Reches A., Burke R.E., Jiang D., Wagner H.R., and Fahn S. Neurotensin interacts with dopaminergic neurons in rat brain. Peptides 4 (1983) 43-48
54. Reinecke M., and Neurotensin. Immunohistochemical localization in central and peripheral nervous system and in endocrine cells and its functional role as neurotransmitter and endocrine hormone. Prog Histochem Cytochem 16 (1985) 1-172
55. Rompre P.P., Bauco P., and Gratton A. Facilitation of brain stimulation reward by mesencephalic injections of neurotensin-(1-13). Eur J Pharmacol 211 (1992) 295-303
56. Seutin V., Massotte L., and Dresse A. Electrophysiological effects of neurotensin on dopaminergic neurones of the ventral tegmental area of the rat in vitro. Neuropharmacology 28 (1989) 949-954
57. Shibata K., and Furukawa T. The mammillary body, a potential site of action of neurotensin in passive avoidance behavior in rats. Brain Res 443 (1988) 117-124
58. Singh J., Desiraju T., and Raju T.R. Effects of microinjections of cholecystokinin and neurotensin into lateral hypothalamus and ventral mesencephalon on intracranial self-stimulation. Pharmacol Biochem Behav 58 (1997) 893-898
59. Steinberg R., Brun P., Fournier M., Souilhac J., Rodier D., Mons G., et al. SR 48692, a non-peptide neurotensin receptor antagonist differentially affects neurotensin-induced behaviour and changes in dopaminergic transmission. Neuroscience 59 (1994) 921-929
60. Tanaka K., Masu M., and Nakanishi S. Structure and functional expression of the cloned rat neurotensin receptor. Neuron 4 (1990) 847-854
61. Tirado-Santiago G., Lazaro-Munoz G., Rodriguez-Gonzalez V., and Maldonado-Vlaar C.S. Microinfusions of neurotensin antagonist SR 48692 within the nucleus accumbens core impair spatial learning in rats. Behav Neurosci 120 (2006) 1093-1102
62. Toth K., Laszlo K., Lukacs E., and Lenard L. Intraamygdaloid microinjection of acylated-ghrelin influences passive avoidance learning. Behav Brain Res 202 (2009) 308-311
63. Tyler-McMahon B.M., Boules M., and Richelson E. Neurotensin: peptide for the next millennium. Regul Pept 93 (2000) 125-136
64. Tzschentke T.M. Measuring reward with the conditioned place preference paradigm: a comprehensive review of drug effects, recent progress and new issues. Prog Neurobiol 56 (1998) 613-672
65. Vincent J.P., Mazella J., and Kitabgi P. Neurotensin and neurotensin receptors. Trends Pharmacol Sci 20 (1999) 302-309
66. Watson G.P.a.C. The rat brain in stereotaxic coordinates (1986), Academic Press, New York
67. Watson M., Isackson P.J., Makker M., Yamada M.S., Yamada M., Cusack B., et al. Identification of a polymorphism in the human neurotensin receptor gene. Mayo Clin Proc 68 (1993) 1043-1048
68. Woodward D.J., Chang J.Y., Janak P., Azarov A., and Anstrom K. Mesolimbic neuronal activity across behavioral states. Ann N Y Acad Sci 877 (1999) 91-112